Antifolates are an important class of anticancer drugs originally developed as anti leu- kemic agents, but now used, usually in combination with other drugs, for the treatment of a wide range of tumors, notably carcinomas of the head and neck, breast, germ cell tumors, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, and osteogenic sar- comas. 5-Fluorouracil and its prodrugs also target, in part, the folate-dependent enzyme, thymidylate synthase. Furthermore, folate supplementation in the form of leucovorin, modulates 5-fluororuacil activity. 5-Fluorouracil is widely used in the treatment of colorectal and gastric cancer and in combination for other solid tumors such as breast and head and neck cancers. Ongoing clinical trials with the newer antifolates suggest that the range of solid tumors where these agents will be of use may broaden further. Half a century ago, interesting scientific and clinical discoveries suggested that folie acid was a vitamin involved in vital cellular metabolic processes. The folate analogs, aminopterin and methotrexate, were synthesized by the American Cyanamid Company in an attempt to interfere with these processes and were shown to have anticancer activity by Farber and his colleagues. Hence, the principle of antimetabolite therapy for the treatment of cancer was established. Biomedical research over the following years led to a deeper understanding of the complex biochemical pharmacology of folates and antifolates. Selective antimicrobial agents were discovered, but more tumor-selective anticancer agents did not immediately emerge.

In this era of biotechnology there have been many books covering the fundamentals of recombinant DNA technology and protein chemistry. However, not many sources are available for the pharmaceutical develop ment scientist and other personnel responsible for the commercialization of the finished dosage forms of these new biopharmaceuticals and other products from biotechnology. This text will help to fill this gap. Once active biopharmaceutical molecules are candidates for clinical trial investigation and subsequent commercialization, a number of other activities must take place while research and development on these molecules continues. The active ingredient itself must be formulated into a finished dosage form that can be conveniently used by health care professionals and patients. Properties of the biopharmaceutical molecule must be clearly understood so that the appropriate finished product formulation can be developed. Finished product formulation development includes not only the chemical formulation, but also the packaging system, the manufacturing process, and appropriate control strategies to assure such good manufacturing practice attributes as safety, identity, strength, purity, and quality.

In recent years cell-based technologies have gained significant scientific attention, and have become a matter of intense public debate as well. Namely, (i) tissue engineering, the construction of tissues and whole organs using molecularly-designed resorbable biomaterials to create new tissue de novo with or without transplanting cells; (ii) the potential use of human embryonic stem cells for transplantation and regenerative medicine (with similar potential for adult-derived stem cells); (iii) and gene therapy, in relation with cell transplantation, have taken their places as the most discussed biomedical issues of the day. New findings in biomimetic materials, cell signalling pathways, extracellular matrix receptors and ligands, growth factors, and the human genome project are motivating the developments in these challenging research areas. This book includes manuscripts on tissue engineering, stem cells and gene therapies authored by world-renowned scientists of the field. The first section of the volume consists of four chapters giving perspectives for the current status and potential future of tissue engineering and stem cell technologies. The second section of the volume includes five chapters based on experimental and clinical data. In this section, the role of stem cells in liver tissue engineering, cell-based therapies in diabetes mellitus, and chronic degenerative diseases of the central nervous system, and adult-derived stem cell therapies are discussed. The two chapters of the third section focus on the biomarkers for tissue-engineered products, namely for tissue-engineered skin. The eight chapters of the fourth section discuss novel biomaterials developed for neural-, vascular-, aortic-, bone-, cartilage- and endocrine pancreas-tissue engineering applications. The last section of the book includes chapters on practical gene targeting applications, controlled release in gene therapy and tissue engineering, antibodies in cancer, acute-phase genes and phage-displayed peptide libraries. Proceedings of BIOMED 2002 The 9th International Symposium on Biomedical Science and Technology, held September 19-22, 2002, in Antalya, Turkey.

This book updates clinicians on the most recent data regarding the medical management of patients of acute coronary syndrome (ACS), providing useful information and expert opinion on the large trials, international guidelines, and clinical practice. It reinforces the need for rapid intervention with pharmacologic therapies to treat and prevent coronary thromboembolism, and to prepare the patient for revascularization procedures, especially percutaneous coronary intervention. Pharmacological Treatment of Acute Coronary Syndromes describes conventional treatment - including anti-ischemic, antiplatelet and anticoagulant therapy - and discusses the clinical use of newer treatment options: the potent new P2Y12 platelet receptor inhibitors with the recently recommended ticagrelor and prasugrel, and new oral anticoagulant agents showing promise for acute management and secondary prevention in ACS. Triple therapy, while not initiated in the acute setting, may impact on future surgical and medical emergencies and their management. Also covered are the various recommendations for each of the antiplatelet and anticoagulant agents in terms of patient selection, pretreatment and timing of therapy, making this book an essential read for a wide range of health professionals.

The most important development in studies of the metabolic effects of anes- thetics has been the recent demonstration that anesthetics may alter the rate of transport of metabolites across biologic membranes. The membranes affected include cell membranes as well as mitochondrial membranes. Inhalation anesthe- tics generally have little effect on glycolysis but may sigrllficantly alter oxidative phosphorylation and mitochondrial oxygen consumption. The direct effects of anesthetics on cell metabolism may be overshadowed in vitro by secondary effects anesthetics exert on endocrine balance, organ blood flow, and changes in oxygen and carbon dioxide tensions. References ALBERS, C., BRENDEL, W., USINGER, W.: Kreislaufrespiratorischer Stoffwechsel undAtmung in Athernarkose. Arch. expo Pathol. Pharmakol., Naunyn-Schmiedeberg's 226, 278 (1955). ALEXANDER, S. C., COHEN, P. J., WOLLMAN, H., SMITH, T. C., REIVICH, ~L, MOLEN, R. A. U.: Cerebral carbohydrate metabolism during hypocarbia in man. Studies during nitrous oxide anesthesia. Anesthesiology 26, 624 (1965). ANDERSEN, N. B.: Effect of general anesthetics on sodium transport in the isolated toad bladder. Anesthesiology 27, 304 (1966). - Synergistic effect of cyclopropane and epinephrine on sodium transport in toad bladder. Anesthesiology 28, 438 (1967). ANNAMUNTHODO, H., KEATING, V., PATRICK, S. J.: Liver glycogen alteration in anaesthesia and surgery. Anaesthesia 13, 429 (1958). APRAHAMIAN, H. A., VANDERVEEN, J. L., BUNKER, J. P., MURPHY, A. J., CRAWFORD, J. D.: The influence of general anesthetics on water and solute excretion in man. Ann. Surg. 100, 122 (1959).

Investigation of the pharmacokinetics and metabolism of human proteins has escalated over the last two decades because of the use of recombinant human proteins as therapeutic agents. In addition, the development and improvement of analytical techniques enabling the detection of minute quantities of proteins in biological matrices have aided this process. In assembling this volume, we sought to provide a state-of-the-art as sessment of the pharmacokinetics and metabolism of protein therapeutics through complete reviews of selected examples. A comprehensive review of all protein therapeutics was not attempted; the majority -of the therapeutic protein classes and crucial scientific issues have been addressed, however. Therefore, we are confident that this volume will provide a useful reference for scientists in this field. The volume has been divided into two general parts. The first part (Chapters 1-3) is composed of general reviews of topics of importance in pharmacokinetic/metabolism studies of proteins: goals and analytical meth odologies, effects of binding proteins, and effects of antibody induction, respectively. The second part (Chapters 4-8) consists of specific, detailed reviews by therapeutic protein class: growth factors and hormones, cyto kines, cardiovascular proteins, hematopoietic proteins, and antibodies, respectively. The editors are grateful to the contributors for the patience, personal sacrifice and perseverance required to complete this volume. BoDDE L. FERRAIOLO MARJORIE A. MOHLER CAROL A. GLOFF ix Contents Chapter 1 Goals and Analytical Methodologies for Protein Disposition Studies Bobbe L. Ferraiolo and Marjorie A. Mohler 1. Introduction ................................................. .

This is truly an exciting time to be in the ?eld of polymer science. Advances in polymerization methods are providing polymer scientists with the ability to specify and control polymer composition, structure, architecture, and molecular weight to a degree that was not possible just a decade ago. This, in turn, is resulting in many novel application possibilities of polymers ranging from drug delivery systems and nanolithographyto stimuli-responsivematerials and many others. In addition,many of the application areas of polymers - such as coatings, adhesives, thermoplastics, composites, and personal care - are also taking advantage of the ability to design polymersduringtheir developmentefforts. Not to forget,manyof these applications of polymers involve mixing polymers with solvents, catalysts, colorants, and many other ingredients to prepare a formulated product. However, the tuning of polymer composition and structure as well as polymer formulations to optimize the ?nal performance properties can be challenging, - pecially since in many cases several interacting variables need to be optimized simultaneously. This is where the methodologies and techniques of combinatorial and high-throughput experimentation to synthesize and characterize polymer - braries can be an invaluable approach. Simply put, a polymer library is a collection of multiple polymer samples having a systematic variation in one or more variables related to composition, structure, or process. Various methods and strategies have been explored to ef?ciently prepare a large number of polymer samples and also to screen these samples for key properties of interest.

Master the latest knowledge and skills you need to work successfully with today's licensed pharmacists in a variety of clinical or retail settings. Moini's THE PHARMACY TECHNICIAN: A COMPREHENSIVE APPROACH, 4E provides readings that explore the latest medical and pharmaceutical terminology, pharmaceutical calculations, and techniques. You examine critical topics, such as sterile compounding, record keeping, law, ethics, insurance, and billing. In addition, effective learning tools help you master medical and pharmaceutical terminology and avoid today's most common errors, all while strengthening your critical thinking and problem-solving skills. In addition, MindTap online learning resources are available to immerse you in today's typical pharmacy setting for hands-on practice with virtual pharmacy activities. Designed for entry-level students, this edition is invaluable for experienced pharmacy technicians pursuing continuing education or for anyone preparing for national certification exams.

Galenical pharmacy or galenics is the science dealing with the pro duction of drug substances from raw materials, the purity of such substances, their formulation into pharmaceutical preparations with the desired effects and safety in use, and the quality control, stability and storage of the preparations. The field has taken its name from the Greek physician Galen (131-201 A.D.), who had a profound influence on medicine for many centuries because he collected and systematized the medicinal knowledge of his time. The discovery of insulin is attributed to Banting and Best who, in 1921, prepared an extract of the pancreas of the fetal calf and showed that the extract was capable of reducing the blood sugar level of a diabetic dog. This outstanding discovery gave rise to the rapid develop ment of the manufacture of insulin of bovine and porcine origin. By 1925, two Danish manufacturers of insulin preparations were established; both have since been in the forefront ofthe development of insulin preparations, the latest achievement being the marketing of human insulin by Novo in 1982. The development of highly purified human insulin produced semisynthetically from porcine insulin or by DNA recombinant methods are significant contributions to safe and efficient insulin therapy. Insulin is a protein which is destroyed in the gastrointestinal tract."

Proceedings of the International Conference on Dipeptidyl Aminopeptidases, held September 26-28, 2002, in Berlin, Germany. Dipeptidyl Aminopeptidases exert a potent modulatory role at an interface between immune mechanisms, metabolic responses and neuroendocrine pathways. Experimental models and clinical studies addressing the role of these enzymes and the effect of specific inhibitors pave the way to novel therapeutic concepts in immunology, rheumatology, oncology, reproductive medicine and diabetes. Leading experts in this field have contributed to this book which presents a state-of-the-art view on these enzymes, at a time when our understanding of their function is growing ever more rapidly and therapeutic options become imminent. The sections of the book focus on various topics: - Structure and function of dipeptidyl aminopeptidases, - DPP IV-like proteins, - Immune mechanisms and immune disorders, - Cancer and angiogenesis, - Diabetes and metabolism, - Therapeutic implications.

Sex matters! Are there differences between the sexes when it comes to brain function and the behaviours that result? This volume attempts to answer this fundamental question. If the answer is 'yes' then this should impact upon our approach to treating mental illness in humans, and to modelling it in animals, as we look for aetiological and pharmacological solutions.

The idea for publishing these books on the mechanism of action and on the biosynthesis of antibiotics was born of frustration in our attempts to keep abreast of the literature. Gone were the years when we were able to keep a biblio graphy on antibiotics and feel confident that we could find everything that was being published on this subject. These fields of investigation were moving for ward so rapidly and were encompassing so wide a range of specialized areas in microbiology and chemistry that it was almost impossible to keep abreast of developments. In our naivete and enthusiasm, however, we were unaware that we were toying with an idea that might enmesh us, that we were creating an entity with a life of its own, that we were letting loose a Golom who instead of being our servant would be our master. That we set up ideals for these books is obvious; they would be current guides to developments and information in the areas of mechanism of action and bio synthesis of antibiotics. For almost every subject, we wished to enlist the aid of an investigator who himself had played a part in determining the nature of the phenomena that were being discussed. One concept for the books was that they include only antibiotics for which a definitive, well-documented mechanism of action or biosynthetic pathway was known.

Contents: V. Zingel, C. Leschke and W. Schunack: Developments in research on histamine (H1) receptor agonists / P.D. Hoeprich: Antifungal chemotherapy / G. de Stevens: The diversity of heterocyclic compounds and their biological activities / R.M. Schultz: Newer antifolate compounds in cancer therapy / P.K. Mehrotra, S. Batra and A.P. Bhadun: Non-steroidal agents for regulation of the menstrual cycle / A.K. Saxena and M. Saxena: Developments in anti-convulsant drugs

With drug information rapidly migrating to the Web, the chronically poor standards of drug information available to consumers in the developed and the developing world are being further compromised. This book offers insight into the uncharted waters of prescription drug information and promotion on the internet and suggests how it might be transformed into an unprecedented agent for good. It traces the social and political history of prescription drug information and marketing to Western consumers, offers a social and communicative profile of prescription drug Web sites, and evaluates the most widely used sources of prescription drug information, from government organizations and information companies and TV-related sites, to health service provider sites, manufacturers' brand sites, and social media, including YouTube and Wikipedia. The focus throughout is on practical outcomes: How can information for consumer decision making be optimized and how can consumers use it responsibly?

La composition particuliere des lipides des Bacteries justifie pleinement la redaction de la presente revue; en effet, les Bacteries elaborent des lipides dont la composition est tres differente de celle des lipides des autres organismes, que ce soient des Champignons, des Algues ou des Animaux superieurs. L'interet porte actuellement a 1'etude des lipides bacteriens est egalement justifie par 1'importance biologique de certaines fractions lipidiques. Le domaine que nous allons resumer est d' ailleurs encore peu developpe; a part des etudes nombreuses et tres detaillees sur les lipides des Myco- bacteries et sur ceux du Bacille diphterique, nous ne possMons que des renseignements sporadiques concernant ceux d'autres especes bacteriennes. R. ]. ANDERSON, a qui nous devons la plus grande partie de nos connaissances sur les lipides des Mycobacteries, a publie dans Ie volume III de la presente collection, une revue intitulee {

These proceedings contain the papers presented at the Bayer-Symposium V which was held in Grosse Ledder on October 16-21, 1973 and which was simultaneously the Second International Research Conference on Proteinase Inhibitors. The cordial atmosphere, the frank discussions and the profitable exchange of ideas during the First International Research Conference on Proteinase Inhibitors which was held on November 4--6, 1970 in Munich were a stimulant for us to consider holding a Second Conference especially as the steadily increasing research activities in this and related fields called for a new assessment of recent efforts in proteinase inhibitor research. In the three years since the First Conference was held, this field has developed particularly in the areas of molecular aspects of protein-protein interactions and in the extension to inhibitors of nonserine proteinases and peptidases. In planning this meeting the Organizing Committee was faced with the problem of selecting a limited number of participants and we decided that it was appropriate and necessary to focus in detail on the chemistry of proteinase inhibitors, their interac tions with a variety of enzymes and also to invite more general papers to survey the physiological and clinical aspects of the subject which we felt would be of importance in the future.

This report on Future Trends in Inflammation IV records another of the multidisciplinary meetings organized by the European Biological Research Association. The organizers wish to record their thanks to all the participants and delegates who made this such an enjoyable meeting. Our thanks are due to a number of members of the pharmaceutical industry who so kindly donated funds. These funds were used to provide grants for young research workers to attend this meeting. Many people have kindly given their time and help to make this congress possible. It is impossible to list them by name, but we are profoundly grateful. We were dubious at the outset as to whether to hold this meeting in a period when many other meetings are being organized on inflammation. The enthusiastic attendance proves that we were right in going ahead. The next international meeting will be held in France in 1983. For further details please contact: Professor J. P. Giroud Department of Pharmacology, Hopital Cochin 75014 Paris, France D. A. Willoughby J. P. Giroud xxxiii Section I Future Trends CHAIRMAN: L. Chedid CO-CHAIRMAN: Dame Honor Fell 1 The participation of mononucleur phagocytes in immune based inflammatory processes with special reference to their secretory responses P. DAVIES AND R. J.

This volume is an important advancement in the application ofpharmacokinetic (PK) and pharmacodynamic (PO) principles to . drug development. The series of topics presented deal with the application of these tools to everyday decisions that a pharmaceutical scientist encounters. The ability to integrate these topics using PK and PO methods has optimized drug development pathways in the clinic. New technologies in the areas of in vitro assays that are more predictive of human absorption and metabolism and advancement in bioanalytical assays are leading the way to minimize drug failures in later, more expensive clinical development programs. of Pharmacokinetics and pharmacodynamics have become an important component understanding the drug action on the body and is becoming increasingly important in drug labeling due to it's potential for predicting drug behavior in populations that may be difficult to study in adequate numbers during drug development. The ability to correlate drug exposure to effect and model it during the drug development value chain provides valuable insight into optimizing the next steps to derive maximum information from each study. These principles and modeling techniques have resulted in an expanded and integrated view of PK and PO and have led to the expectations that we may be able to optimally design clinical trials and eventually lead us to identifying the optimal therapy for the patient, while minimizing cost and speeding up drug development. There is wide utility for the book both as a text and as a reference.

Burgeoning research into marine natural products during the past two decades has in no small measure been due to an heightened and world-wide interest in the ocean, to the development of new sophisticated computer-driven instrumentation, and to major advances in separation science. Organic chemists have been fully aware that processes in living systems occur in an aqueous medium. Nevertheless, the chemists who have specialized in the study of small molecules have found it expedient to use organic rather than aqueous solvents for the isolation and manipulation of secondary metabolites. The emergence of new chromatographic techniques, the promise of rewarding results, not to mention the relevance of polar molecules to life itself, have contributed to a new awareness of the importance of organic chemistry in an aqueous medium. The first chapter in Volume 2 of Bioorganic Marine Chemistry reflects the growing interest and concern with water-soluble com pounds. Quinn, who pioneered the separation of such molecules, has contributed a review which closely links techniques with results and is based on practical experience. The second chapter, by Stonik and Elyakov, examines the vast chemical literature of the phylum Echinodermata - over one fourth of it in difficulty accessible Russian language publications. The Soviet authors evaluate the data for their suitability as chemotaxonomic markers."

Part 3 of the Handbook of Experimental Pharmacology (Concepts in Biochem ical Pharmacology) applies the principles enunciated in Parts 1 and 2 to clinical pharmacology and toxicology. The major objective is to elucidate the many factors that determine the relationships between pharmacokinetic aspects of the disposition and metabolism of drugs and their therapeutic or toxic actions in man. Because of the more restricted information obtainable in human studies, this volume reflects the editors' bias that an understanding of pharmacokinetics is fundamental for assessing pharmacologic or toxicologic effects of drugs in humans. The first chapter is a unique primer on when to apply and how to use pharmaco kinetic tools in human pharmacology. The second chapter explains the general assumptions underlying pharmacokinetic approaches both in simple terms for the novice and in mathematical form for the more sophisticated reader. Several chapters on determinants of drug concentration and activity discuss drug absorption, drug latentiation, drugs acting through metabolites, entero hepatic drug circulation, influence of route of drug administration on response, genetic variations in drug disposition and response, age differences in absorption, distribution and excretion of drugs, and pathologic and physiologic factors affecting absorption, distribution and excretion of drugs and drug response. The focus of these chapters is data obtained in human, rather than animal, studies. Most of the chapters contain new material never summarized previously."

A major vehicle for the transition of carrier-mediated drug delivery from a theoretical/experimental status to one with practical uses has been the NATO Advanced Studies Institute series "Targeting of Drugs." Three previous ASls of the series 1-3], also held in Cape Sounion, dealt with carriers of natural and synthetic origin, their preparation and drug incorporation as well as a wide range of applications. This book contains the proceedings of the 4th NATO ASI "Targeting of Drugs: Anatomical and Physiological Considerations" held in Cape Sounion, Greece during 20 June - 1 July 1987. Historically, carrier systems have been chosen on the basis of selective affinity for target sites. For instance, monoclonal antibodies bind selectively to antigens on the surface of cells and the same applies to ligands such as certain glycoproteins which bind to cell receptors. Colloidal carriers on the other hand, are "passively" targeted to the reticuloendothelial system. However, effective drug delivery depends not only on demonstration of affinity of the carrier system for its target but also, and perhaps crucially, on the way(s) by which the carrier-drug entity interacts with the interposed biological milieu. The book deals in depth with a number of biological milieus as travelled space for carriers en route to their destination, difficulties arising from unfavorable milieu-carrier interactions and ways to circumvent such difficulties. It also identifies, when possible, situations where proposed uses would or would not be realistic and provides perspectives for future goals.

Themulticomponentnatureofbiologicalmembranesandtheirintra- andextracel- lar interactions make direct investigations on the membrane structure and processes nearly impossible. Clearly, a better understanding of the membrane properties and the mechanisms determining membrane protein functions is crucial to the imp- mentation of biosensors, bioreactors and novel platforms for medical therapy. For this reason, the interest in model systems suitable for the construction and study of complex lipid/protein membrane architectures has increased steadily over the years. The classical portfolio of model membranes used for biophysical and - terfacial studies of lipid (bi)layers and lipid/protein composites includes Langmuir monolayers assembled at the water/air interface, (uni- and multi-lamellar) vesicles in bulk (liposomal) dispersion, bimolecular lipid membranes (BLMs), and various types of solid-supported membranes. All these have speci?c advantages but also suffer from serious drawbacksthat limit their technical applications. Polymer m- branes comprised of entirely synthetic or hybrid (synthetic polymer/biopolymer) block copolymersappeared to be an attractive alternative to the lipid-based models. Generally, the synthetic block copolymer membranes are thicker and more stable and the versatility of polymer chemistry allows the adoption of relevant properties for a wide range of applications. This volume provides a vast overview of the physico-chemical and synthetic - pectsofarti?cial membranes. Numerousmembranemodelsaredescribed,including their properties(i. e. swelling, drying,lateral mobility,stability, electrical conduct- ity, etc. ), advantages, and drawbacks. The potential applications of these models are discussed and supported by real examples. Chapter 1 summarizesmethodsfor the stabilizationof arti?cial lipid membranes.